|
Initial Director's Interest Notice - MD
|
22 June 2023 at 12:15pm
|
|
Change of Director's Interest Notice - CB
|
22 June 2023 at 12:15pm
|
|
Final Director's Interest Notice - JW
|
22 June 2023 at 12:15pm
|
|
Update & Changes to the Board
|
22 June 2023 at 12:10pm
|
|
Change in substantial holding - ID
|
18 May 2023 at 11:45am
|
|
Application for quotation of securities - EX1
|
18 May 2023 at 11:00am
|
|
Application for quotation of securities - EX1
|
12 May 2023 at 10:40am
|
|
Notification regarding unquoted securities - EX1
|
12 May 2023 at 10:40am
|
|
Update - Proposed issue of securities - EX1
|
1 May 2023 at 10:20am
|
|
Change in substantial holding - ID
|
28 April 2023 at 1:35pm
|
|
Change of Director's Interest Notice - JW
|
28 April 2023 at 12:40pm
|
|
Results of Meeting
|
28 April 2023 at 11:50am
|
|
Application for quotation of securities - EX1
|
28 April 2023 at 10:55am
|
|
EX1 early stage success with in house Elastin (ELN) program
|
28 April 2023 at 8:30am
|
|
Quarterly Activities Report and Appendix 4C
|
27 April 2023 at 8:35am
|
|
Results of Non-Renounceable Rights Issue
|
26 April 2023 at 8:45am
|
|
Update - Proposed issue of securities - EX1
|
5 April 2023 at 8:40am
|
|
Rights Issue Prospectus and Extension of Closing Date
|
5 April 2023 at 8:40am
|
|
Despatch of Non-Renounceable ProRata Rights Issue Prospectus
|
31 March 2023 at 10:15am
|
|
Notice of General Meeting/Proxy Form
|
29 March 2023 at 8:50am
|
|
Proposed issue of securities - EX1
|
23 March 2023 at 9:15am
|
|
Proposed issue of securities - EX1
|
23 March 2023 at 9:15am
|
|
Exopharm Limited announces Non-Renounceable Pro Rata Rights
|
23 March 2023 at 9:00am
|
|
Notice to Ineligible Shareholder
|
23 March 2023 at 9:00am
|
|
Disclosure Document - Rights Issue Prospectus
|
23 March 2023 at 8:55am
|
|
Notification regarding unquoted securities - EX1
|
9 March 2023 at 12:55pm
|
|
Notice under s708A(12C)(e) of the Corporations Act 2001(Cth)
|
9 March 2023 at 12:55pm
|
|
EX1 to Receive $1m from the Issue of Convertible Notes
|
9 March 2023 at 12:55pm
|
|
Trading Halt
|
9 March 2023 at 9:35am
|
|
EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive
|
9 March 2023 at 8:35am
|
|
Appendix 4D and Half Year Report for period 31 December 2022
|
27 February 2023 at 8:30am
|
|
Initial Director's Interest Notice - CB
|
22 February 2023 at 5:30pm
|
|
Final Director's Interest Notice - JK
|
22 February 2023 at 5:30pm
|
|
Board changes adds Australian capital markets expertise
|
22 February 2023 at 5:30pm
|
|
Ceasing to be a substantial holder
|
15 February 2023 at 4:35pm
|
|
Added Funding for 2023
|
13 February 2023 at 10:50am
|
|
Trading Halt
|
9 February 2023 at 9:45am
|
|
Quarterly Activities Report and Appendix 4C
|
31 January 2023 at 2:10pm
|
|
Notification of cessation of securities - EX1
|
20 December 2022 at 5:35pm
|
|
Final Director's Interest Notice
|
20 December 2022 at 5:35pm
|
|
Operations review, Board and other changes
|
20 December 2022 at 5:20pm
|
|
EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive
|
25 November 2022 at 12:10pm
|
|
Constitution
|
24 November 2022 at 10:30am
|
|
Results of Meeting
|
24 November 2022 at 10:30am
|
|
Exosome manufacture taken to the next level
|
17 November 2022 at 8:45am
|
|
EX1 will commence LEAP technology transfer to AIRM under MSA
|
14 November 2022 at 8:50am
|
|
Upcoming Conference Presentation ANZSEV2022
|
8 November 2022 at 10:30am
|
|
Quarterly Activities Report and Appendix 4C
|
31 October 2022 at 8:35am
|
|
Upcoming Webinar
|
27 October 2022 at 4:10pm
|
|
Exopharm Received R&D Tax Incentive Refund
|
27 October 2022 at 8:35am
|
Exopharm